TOP STORIES

• BUSINESS Daiichi Sankyo Eyes V-Shaped Recovery from Olmesartan Patent Cliff: 5-Year Plan
  April 1, 2016

• BUSINESS HPV Vaccine Makers, Govt to Face Class-Action Suit; MSD Says Plaintiffs’ Claim Unfounded
  March 31, 2016

• INTERVIEW Takeda Linking Arms with a “Reborn” Teva, Sees Turning Point in Market as an Opportunity: Japan Biz Chief Iwasaki
  March 30, 2016

• BUSINESS Mylan Japan Offers Severance Package for 110 Sales Reps
  March 29, 2016

• BUSINESS Torii Looks to Ramp Up Sales in Allergen Sector, Expand Indications for Sublingual Therapies
  March 28, 2016

• BUSINESS MSD Going Full Out for Sakigake-Designated Pembrolizumab, Poised to Bolster Oncology Force
  March 25, 2016

• BUSINESS Hengrui to Apply for Sakigake Designation; Develop New Drugs Alongside Generics in Japan
  March 24, 2016

• ACADEMIA Positioning of Abraxane and Anti-PD-1 Antibodies Will Be Focus of Interest in Revised Guidelines for Gastric Cancer
  March 23, 2016

• BUSINESS Jitsubo Aims to Launch Peptide Generic Drugs Using Its Unique Technologies
  March 22, 2016

• ORGANIZATION FPMAJ Braced for Thorny Path Ahead Even If Sales Tax Postponed, Revenue Falls Would Weigh on Industry: Chief
  March 18, 2016

• ORGANIZATION Discuss Role of Drugs in Overall Social Security System: Full Interview with FPMAJ Pricing Affairs Chief
  March 18, 2016

• REGULATORY Whether to Draw Line between 15 Billion and 100 Billion Yen Sales Thresholds for Re-Pricing Will Hold Key: Kamoya, Nakai
  March 17, 2016

• ACADEMIA It’s Time to Discuss Restart of HPV Vaccine Promotion, Panel Chief Says as Personal View
  March 16, 2016

• REGULATORY Sales Thresholds for Re-Pricing Rule to Be Key Point of Future Discussions: MHLW Pharma Management Director
  March 15, 2016

• REGULATORY No Licensing Deal Clinched for First AMED-Backed Drug Seed
  March 14, 2016

• BUSINESS Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
  March 11, 2016

• ORGANIZATION “Huge-Seller” Re-Pricing Eroding Predictability of Japanese System: FPMAJ’s Kamoya
  March 10, 2016

• BUSINESS Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
  March 9, 2016

• BUSINESS Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
  March 8, 2016

• BUSINESS Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
  March 7, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 169
• 170
• 171
• 172
• 173
• 174
• 175
• 176
• 177
• …
• Next ›
• 最終 »